Table 1.

Patient characteristics and distribution of clinicopathological features in all CLND patients

	N	%
Gender
Female	192	52.2
Male	176	47.8
Age (years)
< 40	75	20.4
40–60	185	50.3
≥60	108	29.3
Mean/median	51/52
Primary tumor site
Head/neck	1	0.3
Upper extremity	54	14.7
Lower extremity	130	35.3
Anterior trunk	49	13.3
Posterior trunk	134	36.4
Primary melanoma Breslow thickness (mm)
≤ 1.0	24	6.7
1.01–2.0	46	12.8
2.01–4.0	127	35.5
>4.0	161	45.0
Data not available	10
Median	4
Primary melanoma level of invasion according to Clark
II	24	6.7
III	122	34.1
IV	158	44.1
V	54	15.1
Data not available	10
Ulceration of melanoma
No	112	32.3
Yes	235	67.7
Data not available	21
Pathological type
NM	205	66.6
SSM	76	24.6
ALM	12	3.9
LMM	15	4.9
Data not available	60
Location of lymph node dissection
Neck	1	0.3
Axillary	212	57.7
Inguinal	152	41.3
Other/mixed	3 (axillary-inguinal)	0.7
Number of lymph nodes with metastases
1	205	56.0
2–3	125	34.2
≥4	36	9.8
Data not available	2
Extracapsular extension of lymph node metastases
No	284	77.2
Yes	84	22.8
Metastases to sentinel nodes only
Yes	262	71.6
No	104	28.4
Data not available	2
Maximal diameter of metastases to sentinel nodea
<0.1 mm	7	2.2
0.1–1.0 mm	105	32.7
>1.0 mm	209	65.1
Microanatomic localization of metastases in SNa
Subcapsular	18	5.6
Combined	149	46.4
Parenchymal	67	20.9
Multifocal	15	4.7
Extensive	72	22.4
Lymph MM RT-PCR assay resultb
Positive	38	27.7
Negative	99	72.3

CLND group patients with regional lymph nodes metastases detected by sentinel lymph node biopsy followed by completion lymph node dissection, NM nodular melanoma, SSM superficial spreading melanoma, ALM acral lentiginous melanoma, LMM lentigo malignant melanoma, SN sentinel lymph node, MM RT–PCR multimarker reverse-transcriptase polymerase chain reaction

^a321 patients

^b137 patients